Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Life Sci ; 81(2): 144-52, 2007 Jun 20.
Article in English | MEDLINE | ID: mdl-17544453

ABSTRACT

Nifurtimox (Nfx) is a nitroheterocyclic drug used in the treatment of Chagas' disease. It has serious side effects which frequently force to interrupt the treatment. Nfx toxicity has been linked to its nitroreduction to a nitroanion radical with a subsequent redox cycling which generate reactive oxygen species. We analyzed the ability of Sprague Dawley male rat pancreas to nitroreduce Nfx and whether this drug may cause deleterious effects in this organ. The microsomal fraction exhibited Nfx nitroreductase activity in the presence of NADPH under anaerobic atmosphere, which was fully inhibited under air but not altered when N2 was replaced by pure CO. The cytosol nitroreduced Nfx in the presence of hypoxanthine under N2; it was inhibited by allopurinol and negligible in aerobiosis. Nfx reached pancreatic tissue at 1, 3 or 6 h after intragastric administration (100 mg/kg). Six hours after drug administration, a significant increase in t-buthylhydroperoxide promoted chemiluminiscence was detected. Pancreatic protein sulfhydryl content significantly decreased at either 1, 3 or 6 h after Nfx administration. No changes in either protein carbonyl or in lipid hydroperoxides were observable. Ultrastructural alterations were observed in the endoplasmic reticulum and nuclei from acinar cells and in the insulin-containing granules from the pancreas. However, the seric amylase levels were not changed, but the blood glucose levels were slightly but significantly increased 24 h after Nfx administration. These studies might suggest that Nfx treatment could impose an increased risk to patients exposed to other insults provoking oxidative stress or having preexisting pathologies in the pancreas.


Subject(s)
Nitroreductases/metabolism , Pancreas/cytology , Pancreas/enzymology , Animals , Cytosol/drug effects , Cytosol/enzymology , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/metabolism , Luminescence , Male , Microscopy, Electron, Transmission , Microsomes/drug effects , Microsomes/enzymology , Nifurtimox/metabolism , Pancreas/ultrastructure , Rats , Rats, Sprague-Dawley , Subcellular Fractions/drug effects , Subcellular Fractions/enzymology , Sulfhydryl Compounds/metabolism , Superoxides/metabolism , tert-Butylhydroperoxide/metabolism
2.
Toxicology ; 191(2-3): 189-98, 2003 Sep 30.
Article in English | MEDLINE | ID: mdl-12965122

ABSTRACT

Benznidazole (Bz) is a drug used in the chemotherapy of the acute and intermediate phases of Chagas' disease (American Trypanosomiasis), an endemic parasitic disease afflicting more than 16 million people in Latin America. Serious toxic side effects of Bz have been reported in treated human beings and in experimental animals. Bz toxicity would be linked to its nitroreductive bioactivation to reactive intermediates and to the corresponding amine known to occur in vivo and mediated by different enzymatic systems. In the present study the presence of Bz nitroreductases in rat esophagus and the occurrence of Bz induced esophageal cell injury are described. Already 1 and 3 h after an intragastric Bz administration to Sprague-Dawley male rats (240-260 g body weight) at a dose of 100 mg/kg esophageal levels of the drug were 66.4+/-4.0 and 149.2+/-14.3 nmol per g tissue, respectively. The esophageal mucosa homogenates exhibited Bz nitroreductase activity attributable to the participation of cytochrome P450 reductase and xanthine oxidoreductase (XOR). The ultrastructural observation of esophageal tissue from Bz treated animals 24 h after its administration evidenced: detachment and conglomeration of polyribosomes, reduction in the presence of desmosomes and of the amount of bacteria on its surface. The potential significance of these alterations is not fully clear at present. However, these deleterious effects might be additive or synergistic with those induced by the evolution of the disease.


Subject(s)
Esophageal Diseases/chemically induced , Gastric Mucosa/drug effects , Nitroimidazoles/toxicity , Trypanocidal Agents/toxicity , Animals , Esophageal Diseases/enzymology , Esophageal Diseases/pathology , Gastric Mucosa/metabolism , Gastric Mucosa/pathology , Histocytochemistry , Male , Microscopy, Electron , Nitroreductases/metabolism , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL